PFE: Pfizer Inc. Company Profile & Statistics

About

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Info & Links

CEO

Albert Bourla

Headquarters

66 HUDSON BOULEVARD EAST
NEW YORK, NY 10001, UNITED STATES

Auditor

KPMG LLP

Share holders

113,116

Employees

81,000

Pfizer Inc. Statistics

Valuation Measures

Market Capitalization²

139.43B

Enterprise Value

200.11B

Enterprise Value/EBITDA(ttm)

10.56

Price to Earnings Ratio(ttm)

8.33

Price to Sales(ttm)

2.31

Price to Book(mrq)

1.59

Price to Cash(ytd)

6.38

Profitability

Gross Margin(ttm)

72.85%

Operating Margin(ttm)

27.85%

Profit Margin(ttm)

12.37%

Return on Equity(ttm)

19.47%

Return on Invested Capital(ttm)

5.28%

Return on Assets(ttm)

8.09%

Income Statement

Revenue(ttm)

62.46B

Revenue Per Share(ttm)

10.99

Gross Profit(ttm)

45.15B

EBITDA(ttm)³

18.94B

Net Income Available to Common(ttm)

7.88B

Diluted EPS(ttm)

1.41

Share Statistics

Beta (5Y Monthly)

0.64

52-Week Change

-10.92%

S&P 500 52-Week Change

9.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

5.69B

Dividend Yield

6.64%

Float⁴

5.66B

% Held by Insiders

0.06%

% Held by Institutions

68.36%

Balance Sheet

Total Cash(mrq)

17.32B

Total Cash Per Share(mrq)

3.05

Total Debt(mrq)

62.11B

Total Debt/Equity(mrq)

68.52%

Current Ratio(mrq)

1.26%

Quick Ratio(mrq)

0.73%

Book Value Per Share(mrq)

15.94

Cash Flow

Operating Cash Flow Per Share(ytd)

0.41

Free Cash Flow(ytd)

1.77B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

PFE

Pfizer Inc.

Pfizer Inc. Profile